http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3166970-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_baee372c55802742f9582e25c15ff11a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdbcd91afe222be9465f712aaa12d7ee
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
filingDate 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12ca6571e51a5f27e5c8bae0e7c51b36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a686539c627509e9623ee794b5d12cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19393a79fd1034877ba0cdb04d3c26a6
publicationDate 2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3166970-A2
titleOfInvention IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
abstract The present invention relates to the amyloid beta peptide (Aβ) and more specifically to antibodies binding to Aβ protofibrils and their use in therapy and/or prophylactic treatment of Alzheimer's disease and other disorders associated with Aβ protein aggregation. Further the invention may relate to diagnosis of such diseases as well as monitoring of disease progression by use of the antibodies of the invention. Further, the invention may relate to veterinary use of the antibodies of the invention.
priorityDate 2014-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421590
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226530095
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10444661
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID378
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6365177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19751209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422855

Total number of triples: 42.